Literature DB >> 34141083

Structure-Activity Relationship for the Picolinamide Antibacterials that Selectively Target Clostridioides difficile.

Enrico Speri1, Yuanyuan Qian1, Jeshina Janardhanan1, Cesar Masitas1, Elena Lastochkin1, Stefania De Benedetti1, Man Wang1, Valerie A Schroeder1, William R Wolter2, Allen G Oliver1, Jed F Fisher1, Shahriar Mobashery1, Mayland Chang1.   

Abstract

Clostridioides difficile is a leading health threat. This pathogen initiates intestinal infections during gut microbiota dysbiosis caused by oral administration of antibiotics. C. difficile is difficult to eradicate due to its ability to form spores, which are not susceptible to antibiotics. To address the urgent need for treating recurrent C. difficile infection, antibiotics that selectively target C. difficile over common gut microbiota are needed. We herein describe the class of picolinamide antibacterials which show potent and selective activity against C. difficile. The structure-activity relationship of 108 analogues of isonicotinamide 4, a compound that is equally active against methicillin-resistant Staphylococcus aureus and C. difficile, was investigated. Introduction of the picolinamide core as exemplified by analogue 87 resulted in exquisite potency and selectivity against C. difficile. The ability of the picolinamide class to selectively target C. difficile and to prevent gut dysbiosis holds promise for the treatment of recurrent C. difficile infection.
© 2021 American Chemical Society.

Entities:  

Year:  2021        PMID: 34141083      PMCID: PMC8201750          DOI: 10.1021/acsmedchemlett.1c00135

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.632


  28 in total

1.  Fidaxomicin versus vancomycin for Clostridium difficile infection.

Authors:  Thomas J Louie; Mark A Miller; Kathleen M Mullane; Karl Weiss; Arnold Lentnek; Yoav Golan; Sherwood Gorbach; Pamela Sears; Youe-Kong Shue
Journal:  N Engl J Med       Date:  2011-02-03       Impact factor: 91.245

Review 2.  Targeting cancer with small molecule kinase inhibitors.

Authors:  Jianming Zhang; Priscilla L Yang; Nathanael S Gray
Journal:  Nat Rev Cancer       Date:  2009-01       Impact factor: 60.716

Review 3.  Clostridium difficile--more difficult than ever.

Authors:  Ciarán P Kelly; J Thomas LaMont
Journal:  N Engl J Med       Date:  2008-10-30       Impact factor: 91.245

4.  Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease.

Authors:  Wafa N Al-Nassir; Ajay K Sethi; Yuejin Li; Michael J Pultz; Michelle M Riggs; Curtis J Donskey
Journal:  Antimicrob Agents Chemother       Date:  2008-04-28       Impact factor: 5.191

5.  Intestinal dysbiosis and depletion of butyrogenic bacteria in Clostridium difficile infection and nosocomial diarrhea.

Authors:  Vijay C Antharam; Eric C Li; Arif Ishmael; Anuj Sharma; Volker Mai; Kenneth H Rand; Gary P Wang
Journal:  J Clin Microbiol       Date:  2013-06-26       Impact factor: 5.948

Review 6.  Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence.

Authors:  Konstantinos Z Vardakas; Konstantinos A Polyzos; Konstantina Patouni; Petros I Rafailidis; George Samonis; Matthew E Falagas
Journal:  Int J Antimicrob Agents       Date:  2012-03-06       Impact factor: 5.283

7.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

Authors:  T Mosmann
Journal:  J Immunol Methods       Date:  1983-12-16       Impact factor: 2.303

Review 8.  Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain.

Authors:  Jennifer R O'Connor; Stuart Johnson; Dale N Gerding
Journal:  Gastroenterology       Date:  2009-05-07       Impact factor: 22.682

9.  Lactobacillus gasseri APC 678 Reduces Shedding of the Pathogen Clostridium difficile in a Murine Model.

Authors:  Lisa Quigley; Mairéad Coakley; Debebe Alemayehu; Mary C Rea; Patrick G Casey; Órla O'Sullivan; Eileen Murphy; Barry Kiely; Paul D Cotter; Colin Hill; R Paul Ross
Journal:  Front Microbiol       Date:  2019-02-20       Impact factor: 5.640

Review 10.  Cost of hospital management of Clostridium difficile infection in United States-a meta-analysis and modelling study.

Authors:  Shanshan Zhang; Sarah Palazuelos-Munoz; Evelyn M Balsells; Harish Nair; Ayman Chit; Moe H Kyaw
Journal:  BMC Infect Dis       Date:  2016-08-25       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.